- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00475423
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
February 4, 2015 updated by: Hoffmann-La Roche
An Open Label Study of a Fixed Dose Regimen of MabThera on Overall Response Rate in Patients With Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura.
This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP).
Patients will receive infusions of MabThera 1000mg i.v. on days 1 and 15.
The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
122
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Adelaide, New South Wales, Australia, 5011
-
Gosford, New South Wales, Australia, 2250
-
Randwick, New South Wales, Australia, NSW 2031
-
Sydney, New South Wales, Australia, 2139
-
Sydney, New South Wales, Australia, 2747
-
Westmead, New South Wales, Australia, 2145
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
-
Malvern, Victoria, Australia, 3144
-
Melbourne, Victoria, Australia, 3168
-
Parkville, Victoria, Australia, 3052
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patients, >=18 years of age;
- refractory, relapsing or chronic idiopathic thrombocytopenic purpura;
- stable therapy during 3 weeks prior to study entry.
Exclusion Criteria:
- newly diagnosed ITP (<6 weeks);
- prior treatment with MabThera;
- active bleeding requiring platelet transfusion within 7 days prior to entry into study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
1000mg iv on days 1 and 15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)
Time Frame: Week 8
|
Percentage of participants with an overall response at Week 8 achieving a CR or PR as evaluated by platelets, new or increased Idiopathic Thrombocytopenic Purpura (ITP)-related treatments and corticosteroids given for Adverse Events (AEs).
CR was defined as a platelet count of greater than (>) 150x10^9/ liters (L) over at least 2 consecutive measurements at least 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
PR was defined as platelet count of >50x10^9/L over at least 2 consecutive measurements at least <2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Overall response rate (participants who achieved CR or confirmed PR) was evaluated using platelets, new or increased ITP related treatments, and corticosteroids given for AEs.
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Hematological CR, PR, or Minor Response (MR)
Time Frame: Week 8
|
Percentage of participants with CR, PR, and MR at Week 8 as evaluated by platelet count where CR is greater than or equal to (≥)150x10^9/L, PR ≥ 50x10^9/L, MR equals (=) 30x10^9/L over 2 consecutive measurements at least 2 weeks apart but no more than 60 days apart with no increase in concomitant therapy or initiation of new ITP therapy.
|
Week 8
|
Percentage of Participants Who Achieved CR
Time Frame: Week 52
|
CR was defined as platelet counts >150x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 52
|
Time to CR
Time Frame: Baseline to Week 52
|
Time to CR was defined as the time from the first infusion to the first date on which CR was achieved.
CR was defined as platelet counts >150x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Participants without an event were censored at the date of last assessment.
|
Baseline to Week 52
|
Percentage of Participants Who Achieved PR
Time Frame: Week 52
|
PR was defined as platelet counts >50x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 52
|
Time to PR
Time Frame: Baseline to Week 52
|
Time to response was defined as the time from the first infusion to the first date on which PR was achieved.
PR was defined as platelet counts > 50x10^9/L over ≥ 2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Baseline to Week 52
|
Percentage of Participants Who Achieved MR
Time Frame: Week 52
|
MR was defined as participants registered with chronic ITP with a platelet count of >30x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 52
|
Time to MR
Time Frame: Baseline to Week 52
|
Time to response was defined as the time from the first infusion to the first date on which MR was achieved.
MR was defined as participants registered with chronic ITP with a platelet count of >30x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 percent (%) to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Baseline to Week 52
|
Percentage of Participants With Continued CR From Week 8 to Week 52
Time Frame: Week 8 to Week 52
|
The number of participants with a durable CR assessed in CR responders whose responses were sustained from Week 8 through to the end of the study or withdrawal, irrespective of change of treatment.
CR was defined as platelet counts >150x10^9/L over ≥2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 8 to Week 52
|
Duration of CR in Participants With Continued CR From Week 8 Until Week 52
Time Frame: Week 8 to Week 52
|
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of CR, irrespective of change of treatment.
CR was defined as platelet counts >150x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 8 to Week 52
|
Duration of PR in Participants With Continued PR From Week 8 Until Week 52
Time Frame: Week 8 to Week 52
|
Duration of PR was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of PR, irrespective of change of treatment.
PR was defined as platelet counts >50x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 8 to Week 52
|
Duration of MR in Participants With Continued MR From Week 8 Until Week 52
Time Frame: Week 8 to Week 52
|
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of MR, irrespective of change of treatment.
MR was defined as participants registered with ITP in relapse with a platelet count of > 30x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Participants registered with chronic ITP with a platelet count of >30x10^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50% to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
|
Week 8 to Week 52
|
Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event
Time Frame: Week 52
|
Percentage of participants with an event of initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
|
Week 52
|
Time to Initiation of New ITP Therapy
Time Frame: Baseline to Week 52
|
Median time in days to initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
|
Baseline to Week 52
|
Percentage of Therapeutic Responders
Time Frame: Week 26 and Week 52
|
Percentage of participants with a therapeutic response, defined as achieving CR, PR, or MR assessed at Week 26 and Week 52 or hematological response, defined as achieving CR, PR, or MR at Week 8. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
PR response was defined as at least a minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
MR was defined as at least a minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
|
Week 26 and Week 52
|
Percentage of Participants With a Therapeutic Response
Time Frame: Week 26 and Week 52
|
Number of therapeutic responder participants by CR, PR, MR, or no response (NR) measured at Week 26 and Week 52.
CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
PR was defined as at least minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
MR was defined as at least minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
|
Week 26 and Week 52
|
Cluster of Differentiation 19 (CD19) B Cell Count
Time Frame: Baseline, Weeks 1, 3, and 8, Follow-up Months 4, 6, 8, 10, and 12, and Last Day
|
Value of mean CD19+ B cell count at baseline.
The standard reference range for CD19 is 0.05 to 0.35 x10^9/L.
|
Baseline, Weeks 1, 3, and 8, Follow-up Months 4, 6, 8, 10, and 12, and Last Day
|
Change From Baseline in CD19 B Cell Count
Time Frame: Weeks 3, 8 and Months 4, 6, 8, 10 and 12, and last day
|
Actual values of CD19+ mean B cell count assessed at Weeks 3 and 8, and Months 4, 6, 8, 10 and 12, and last day.
The standard reference range for CD19 is 0.05 to 0.35 x10^9/L.
|
Weeks 3, 8 and Months 4, 6, 8, 10 and 12, and last day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
May 17, 2007
First Submitted That Met QC Criteria
May 17, 2007
First Posted (Estimate)
May 21, 2007
Study Record Updates
Last Update Posted (Estimate)
February 23, 2015
Last Update Submitted That Met QC Criteria
February 4, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- ML20948
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Thrombocytopenic Purpura
-
Protalex, Inc.TerminatedPhase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITPIdiopathic Thrombocytopenic Purpura (ITP)Australia, New Zealand
-
CSL LimitedCompletedIdiopathic Thrombocytopenic Purpura (ITP)Australia
-
University Hospital, BordeauxCompletedChronic Idiopathic Thrombocytopenic Purpura | Congenital Thrombocytopenia
-
University Hospital, AngersMinistry of Health, FranceUnknownAcute Idiopathic Thrombocytopenic PurpuraFrance
-
Neufeld, Ellis J, MD, PhDGenentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...CompletedImmune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)United States
-
AmgenCompletedThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic PurpuraUnited States, Canada, Australia
-
Weill Medical College of Cornell UniversityGenentech, Inc.WithdrawnIdiopathic Thrombocytopenic Purpura (ITP)United States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Idiopathic Thrombocytopenic PurpuraChina
-
GlaxoSmithKlineCompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicJapan
-
AmgenCompletedIdiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Clinical Trials on rituximab [MabThera/Rituxan]
-
University of VermontGenentech, Inc.Completed
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaItaly, Brazil, Slovenia, Spain, Germany, Switzerland, Russian Federation, Israel, Sweden, Albania, Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Colombia, Croatia, Ecuador, Egypt, Finland, Greece, Mexico, Romania, Slovakia, ...
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedRheumatoid ArthritisFinland
-
Hoffmann-La RocheCompleted
-
East Carolina UniversityGenentech, Inc.CompletedPulmonary Alveolar Proteinosis | Primary DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaFrance
-
Hoffmann-La RocheCompletedLymphocytic Leukemia, ChronicSweden
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaGermany